E2408: Fast Facts

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Arm A: Rituximab 375 mg/m^2 d 1
Bendamustine 90 mg/m^2 d 1, 2
X 6 cycles every 28 ⇒ Rituximab 375 mg/m^2 Every 8 weeks for 2 yrs

Arm B: Rituximab 375 mg/m2 IV d 1
Bortezomib 1.3 mg/m2 IV d 1, 4, 8, and 11
Bendamustine 90 mg/m2 IV d 1 and 4
X 6 cycles every 28 days ⇒ Rituximab 375 mg/m2 Every 8 weeks for 2 yrs

Arm C: Rituximab 375 mg/m2 IV d1
Bendamustine 90 mg/m2 IV d1,2
X 6 cycles every 28 days ⇒ Lenalidomide 20 mg po d 1-21 every 28 days for 13 cycles
Rituximab 375 mg/m2 every 8 weeks for 2 yrs

Major Eligibility

- Patient must have a histologically confirmed (biopsy-proven) diagnosis of Follicular B-cell non-Hodgkin Lymphoma grades 1, 2, and 3a with no evidence of transformation to large cell histology.
- Patient must meet criteria for High Tumor Burden (higher risk) as defined GELF or FLIPI criteria
- To meet GELF patient must have at least one of the following criterion:
  - Nodal or extranodal mass ≥ 7cm
  - At least 3 nodal masses > 3cm
  - B symptoms
  - Splenomegaly-spleen> 16cm by CT
  - Evidence of compression syndrome
  - Leukemic presentation >5.0 X 10^9/L malignant circulating cells
  - Cytopenias (PMN leukocytes < 1.0 X 10^9/L, Hg < 10gm/dL, and/or platelets <100 x 10^9/L).

  OR
- To meet FLIPI, patient must score at least 3 or more w/ 1 point for each criterion below
  - Age ≥ 60
  - Ann Arbor stage III-IV
  - Hemoglobin <12 mg/dL
  - >4 nodal areas
  - LDH >normal
- Must have stage II, III, or IV disease
- Patients must have NO prior chemo, radiation or immunotherapy for lymphoma
- ECOG PS=0-2
- HIV + allowed if they meet specific criteria (see 3.1.6)
- ANC ≥1500, plt ≥ 100, creat ≤ 2.0, AST/ALT, Alk Phos ≤ 5XULN, Total bilirubin ≤ 1.5X ULN
- No active malignancies as per 3.1.7 (ok if have been disease free for 2 years)
- NO active infections
- NO ≥ Grade 2 neuropathy
- NO myocardial infarction w/I 6 mo of therapy

PRE-STUDY LABS AND TESTS:

- PET, AND contrast CT neck ,chest, abdomen, pelvis ≤ 6 weeks
- **Bilateral** Bone Marrow Biopsy ≤ 8 weeks with optional research sample
- ≤ 4 weeks-CBC,w/ differential, Platelet, Electrolytes, Glucose, Creatinine, Ca, AST, ALT, Uric Acid, Total bili, (Direct bili if total is↑,) Alkaline phosphatase, LDH, B2 Microglobulin, TSH, Hepatitis B Surface antigen and core antigen, CD4/Viral load (HIV+ patients only), Pregnancy test, QOL, Peripheral Blood for research.

Study Coordinator: Leslie Gilbert 262-9818/ pager 3253 3/15/11